Abstract
'Metronomic chemotherapy' represents a novel anti-angiogenic strategy whereby low-dose chemotherapy is utilized in a continuous fashion in order to target tumor endothelium. There are many potential advantages of this strategy and clinical trials are already underway. However, although the scheduling of metronomic chemotherapy is relatively unequivocal, metronomic dosing principles are at present poorly defined. Arbitrarily, 10-33% of the maximum tolerated dose comprises 'the dose range'. We argue that this is too empirical and propose a set of phase I metronomic chemotherapy dosing strategies based on a principled approach which may help to reduce the problem of empiricism in dosing for metronomic chemotherapy trials.
Original language | English |
---|---|
Pages (from-to) | 113-121 |
Number of pages | 9 |
Journal | Anti-Cancer Drugs |
Volume | 17 |
Issue number | 2 |
DOIs | |
Publication status | Published - Feb 2006 |
Keywords
- endothelial growth cells
- growth factor
- metastatic colorectal cancer
- low dose cycophosphamide
- acquired drug resistance
- tumor angiogenesis
- breast cancer
- cell proliferation
- stem cells
- survival
- therapy